Skip to content

Study · In vitro (cells) · 2016

6 results

Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.

Ibáñez-Costa A, Rivero-Cortés E, Vázquez-Borrego MC, Gahete MD, Jiménez-Reina L, Venegas-Moreno E, de la Riva A, Arráez MÁ, González-Molero I, Schmid HA, Maraver-Selfa S, Gavilán-Villarejo I and 6 more

Show all authors

García-Arnés JA, Japón MA, Soto-Moreno A, Gálvez MA, Luque RM, Castaño JP

The Journal of endocrinology1 Sept 2016Cited by 57 (Europe PMC)

PMID27587848 (opens in a new tab)DOI10.1530/joe-16-0332 (opens in a new tab)PepBankPUB-27587848
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In somatotropinoma cells, pasireotide reduced intracellular calcium less efficiently than octreotide.

    In plain wordsIn somatotropinoma cells, pasireotide reduced intracellular calcium less efficiently than octreotide.

    Peptide
    Pasireotide
    Outcome
    IncreaseIntracellular calcium in somatotropinomas
    Study

    humann: not reported in source

    Somatotropinoma cultures
    Comparator
    Octreotide
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    yet octreotide reduced [Ca2+]i more efficiently than pasireotide,
    1 context sentence
    Summary · context
    To explore the cellular/molecular features associated with octreotide/pasireotide response, we performed a parallel comparison of their in vitro effects, evaluating sst1-sst5 expression, intracellular Ca2+ signaling ([Ca2+]i), hormone secretion and cell viability, in…
  2. 02LabIn vitro (cells)Efficacy outcome

    In somatotropinoma cells, pasireotide and octreotide similarly decreased GH release, GH expression and cell viability.

    In plain wordsIn cells from growth hormone-producing tumors, pasireotide and octreotide similarly decreased growth hormone release, growth hormone expression and cell viability.

    Peptide
    Pasireotide
    Outcome
    No significant changeGH release, GH expression and cell viability
    Study

    humann: not reported in source

    Somatotropinoma cultures
    Comparator
    Octreotide
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Somatotropinomas expressed sst5>sst2, yet octreotide reduced [Ca2+]i more efficiently than pasireotide, while both SSA similarly decreased growth hormone release/expression and viability.
    1 context sentence
    Summary · context
    To explore the cellular/molecular features associated with octreotide/pasireotide response, we performed a parallel comparison of their in vitro effects, evaluating sst1-sst5 expression, intracellular Ca2+ signaling ([Ca2+]i), hormone secretion and cell viability, in…
  3. 03LabIn vitro (cells)Efficacy outcome

    In corticotropinoma cells, the response to pasireotide was limited.

    In plain wordsIn corticotropinoma cells, the response to pasireotide was limited.

    Peptide
    Pasireotide
    Outcome
    Direction not reportedCorticotropinoma functional response
    Study

    humann: not reported in source

    Corticotropinoma cultures
    Outcome group
    Tumor cell response · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Corticotropinomas predominantly expressed sst5, but displayed limited response to pasireotide, while octreotide reduced functional endpoints.
    1 context sentence
    Summary · context
    To explore the cellular/molecular features associated with octreotide/pasireotide response, we performed a parallel comparison of their in vitro effects, evaluating sst1-sst5 expression, intracellular Ca2+ signaling ([Ca2+]i), hormone secretion and cell viability, in…
  4. 04LabIn vitro (cells)Efficacy outcome

    In non-functioning pituitary adenoma cells, pasireotide increased cell viability.

    In plain wordsIn non-functioning pituitary adenoma cells, pasireotide increased cell viability.

    Peptide
    Pasireotide
    Outcome
    IncreaseNon-functioning adenoma viability
    Study

    humann: not reported in source

    Non-functioning pituitary adenoma cultures
    Outcome group
    Cell viability and death · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Non-functioning adenomas preferentially expressed sst3 but, surprisingly, both SSA increased cell viability.
    1 context sentence
    Summary · context
    To explore the cellular/molecular features associated with octreotide/pasireotide response, we performed a parallel comparison of their in vitro effects, evaluating sst1-sst5 expression, intracellular Ca2+ signaling ([Ca2+]i), hormone secretion and cell viability, in…
  5. 05LabIn vitro (cells)Efficacy outcome

    In prolactinoma cells, pasireotide produced virtually no response.

    In plain wordsIn prolactinoma cells, pasireotide produced virtually no response.

    Peptide
    Pasireotide
    Outcome
    No significant changeProlactinoma response
    Study

    humann: not reported in source

    Prolactinoma cultures
    Outcome group
    Tumor cell response · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Prolactinomas mainly expressed sst1 but were virtually unresponsive to SSA.
    1 context sentence
    Summary · context
    To explore the cellular/molecular features associated with octreotide/pasireotide response, we performed a parallel comparison of their in vitro effects, evaluating sst1-sst5 expression, intracellular Ca2+ signaling ([Ca2+]i), hormone secretion and cell viability, in…
  6. 06LabIn vitro (cells)Efficacy outcome

    In normal pituitary cells, pasireotide decreased intracellular calcium.

    In plain wordsIn normal pituitary cells, pasireotide decreased intracellular calcium.

    Peptide
    Pasireotide
    Outcome
    DecreaseIntracellular calcium in normal pituitary cells
    Study

    humann: not reported in source

    Normal pituitary cultures
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Finally, both SSA decreased [Ca2+]i in normal pituitaries.
    1 context sentence
    Summary · context
    To explore the cellular/molecular features associated with octreotide/pasireotide response, we performed a parallel comparison of their in vitro effects, evaluating sst1-sst5 expression, intracellular Ca2+ signaling ([Ca2+]i), hormone secretion and cell viability, in…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.